The latest attempt to spotlight Gilead Sciences and its business practices shifted on Thursday to Congress, where a sometimes contentious hearing was held to explore the cost of an HIV prevention pill the company sells and the role the federal government played in discovering the pricey medicine.

The three-hour session was punctuated by a mix of bipartisan sparring that, at times, addressed the larger issue of patients versus profits as much as the Gilead pill, which is called Truvada and has been the focus of intense controversy in recent weeks. The hearing was pushed by AIDS activists, who also filed a lawsuit this week accusing Gilead of anti-competitive behavior to profit off its HIV pill.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy